An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Trial Profile

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Entrectinib (Primary)
  • Indications Anaplastic large cell lymphoma; Breast cancer; Cancer; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Gastrointestinal cancer; Head and neck cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Solid tumours; Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms STARTRK-2
  • Sponsors Ignyta
  • Most Recent Events

    • 20 Jan 2018 Results (n=3) assessing efficacy of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions, were presented at the 2018 Gastrointestinal Cancers Symposium.
    • 06 Nov 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
    • 06 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top